|
|
Article: Product Supply Issues Expected To Impact Nabi's Q3 Pharmaceutical Results; Results from StaphVAX Phase III Clinical Trial To Be Presented at ICAAC.
- Article from:
- PR Newswire
- Article date:
- September 19, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOCA RATON, Fla., Sept. 19 /PRNewswire/ --
Nabi (Nasdaq: NABI) announced today that earnings from its pharmaceutical operations for the third quarter of 2000 will be adversely affected by limited availability of products manufactured for the company by Cangene Corporation. Nabi markets WinRho SDF(R) (RhoD Immune Globulin (Human)) in the United States under a profit sharing agreement with Cangene, which owns and manufactures the product. Cangene is also the contract manufacturer for Nabi-HB(TM) (Hepatitis B Immune Globulin (Human)).
Cangene initiated development of clinical lots of a new product at its facility in Canada earlier in 2000. This new product ...